Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers
Author:
Funder
Novartis
Publisher
Elsevier BV
Subject
Pharmacology (medical),Biochemistry, medical,Pulmonary and Respiratory Medicine
Reference17 articles.
1. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects;Vaidya;Pulm. Pharmacol. Therapeut.,2016
2. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial;Altman;BMC Pulm. Med.,2018
3. Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices;Hira;PloS One,2018
4. Lung delivery of indacaterol and mometasone furoate following inhalation of QMF149 in healthy volunteers;Vaidya;Clin Pharmacol Drug Dev,2016
5. Mometasone furoate delivered via the Breezhaler® and Twisthaler® devices in asthma;Kanniess;Eur. Respir. J.,2014
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dry powder inhalation, part 2: the present and future;Expert Opinion on Drug Delivery;2022-08-19
2. Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies;Journal of Asthma;2022-05-30
3. Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A Combination Therapy for Asthma;Current Respiratory Medicine Reviews;2022-05
4. A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma;Advances in Therapy;2022-01-24
5. Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma;Pulmonary Pharmacology & Therapeutics;2021-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3